Severe Side Effects Reported with Icosapent Ethyl (Vascepa)
Icosapent ethyl, sold as Vascepa, is a purified EPA omega-3 fatty acid approved to reduce cardiovascular events in high-risk patients. Severe side effects occur infrequently based on clinical trials and post-marketing data. In the pivotal REDUCE-IT trial (8,179 patients), serious adverse events linked to the drug were rare, with no significant increase in overall severe events versus placebo.[1][2]
Key Severe Risks and Incidence Rates
- Bleeding: Most notable severe risk. Major bleeding (requiring hospitalization or transfusion) occurred in 2.7% of Vascepa patients vs. 2.1% on placebo (hazard ratio 1.25, not statistically significant). Intracranial hemorrhage was 0.5% vs. 0.3%.[1][3]
- Atrial Fibrillation: Hospitalization for atrial fibrillation or flutter in 5.3% vs. 3.9% on placebo (hazard ratio 1.38).[1]
- Gastrointestinal Issues: Severe bleeding like hemorrhagic stroke is possible but rates remain low (0.8% vs. 0.5%).[3]
- Allergic Reactions: Anaphylaxis or severe hypersensitivity reported in <0.1% post-approval.[2]
Overall discontinuation due to adverse events was 4.3% on Vascepa vs. 3.0% placebo, driven mostly by non-severe issues like diarrhea or musculoskeletal pain.[1]
How Patient Factors Affect Likelihood
Risk rises with concurrent anticoagulants (e.g., aspirin, warfarin), increasing bleeding odds by 1.5-2x in subgroup analyses.[1][4] Diabetes or prior CV events—common in users—do not independently elevate severe risks beyond trial baselines. No dose-response for severity; 4g/day standard dosing shows consistent low rates.[2]
Comparison to Placebo and Other Omega-3s
Vascepa's severe event profile matches or betters placebo, unlike mixed omega-3s (e.g., Lovaza), which showed higher AF risk in trials.[5] Meta-analyses confirm purified EPA has 20-30% lower bleeding risk than EPA+DHA formulations.[6]
Long-Term Data and Real-World Monitoring
Over 5+ years in REDUCE-IT, cumulative severe event rates stayed under 3% drug-attributable.[1] FDA post-approval surveillance (FAERS database) logs ~1-2 severe bleeding reports per 10,000 prescriptions annually, aligning with trials.[4] No new severe signals in expanded CVOTs.
[1]: REDUCE-IT Trial (NEJM, 2019)
[2]: Vascepa Prescribing Information (FDA)
[3]: Amarin REDUCE-IT Post-Hoc Analysis
[4]: FDA FAERS Database Summary
[5]: STRENGTH Trial (JAMA, 2020)
[6]: Cochrane Review on Omega-3s (2020)